Recent studies have reported xCT (SLC7A11), in particular, as a drug resistance maker and a novel target for therapeutic interventions in lung, breast, head & neck, and bladder cancers [35, 38–43]. The gene discussed is SLC7A11; the disease is urinary bladder cancer.